Clinical Research Directory
Browse clinical research sites, groups, and studies.
Effect of Curcumin Add-On Therapy on Quality of Life and IL-1β Levels in Patients With Schizophrenia
Sponsor: Rinvil Renaldi
Summary
This study aims to evaluate the effect of curcumin extract as an adjuvant therapy on quality of life and inflammatory markers in patients with schizophrenia receiving risperidone. Schizophrenia is associated with impaired quality of life and increased inflammatory activity, including elevated levels of interleukin-1 beta (IL-1β). In this randomized clinical trial, patients with schizophrenia are assigned to receive either risperidone alone or risperidone combined with curcumin extract for 8 weeks. Quality of life is assessed using the WHOQOL-BREF questionnaire, and serum IL-1β levels are measured at baseline and after the intervention. The study investigates whether curcumin, known for its anti-inflammatory and antioxidant properties, can improve clinical outcomes and reduce systemic inflammation in patients with schizophrenia.
Official title: The Effect of Adjuvant Curcumin Extract on Quality of Life and Interleukin-1 Beta (IL-1β) Levels in Patients With Schizophrenia Receiving Risperidone: A Randomized Clinical Trial
Key Details
Gender
MALE
Age Range
20 Years - 45 Years
Study Type
INTERVENTIONAL
Enrollment
44
Start Date
2025-11-01
Completion Date
2026-01-31
Last Updated
2026-04-14
Healthy Volunteers
No
Conditions
Interventions
Curcumin
Curcumin extract 1000 mg/day administered orally as an adjuvant therapy in combination with risperidone for 8 weeks.
Risperidone 4mg/day
Risperidone 4 mg/day administered orally as standard antipsychotic therapy for 8 weeks.
Locations (1)
Rumah Sakit Khusus Daerah (RSKD) Dadi Provinsi Sulawesi Selatan
Makassar, South Sulawesi, Indonesia